IVF denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for IVF are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana's Not-FDA-Approved Denial Arises for IVF — and What to Do About It

This denial type in the IVF context rarely applies to IVF itself — the core IVF procedure is a medical service, not a drug or device requiring FDA approval in the conventional sense. When Humana issues a not-FDA-approved denial in connection with IVF, it most commonly targets: a specific laboratory technique or device used in the embryology lab (such as a particular culture system or time-lapse imaging platform), a medication being used in a manner or combination not reflected in its FDA-approved labeling, or an adjuvant treatment added to the IVF protocol. It can also arise from a coding mismatch where a procedure has been billed under a code that Humana's system flags as lacking regulatory clearance.

## Why This Denial Is Appealable

FDA approval and regulatory clearance are not the same as coverage eligibility, and Humana's own medical policies typically distinguish between these concepts. A technique or device with FDA 510(k) clearance, for example, may satisfy a coverage criterion even if it lacks full premarket approval. Similarly, medications used in ways consistent with recognized reproductive medicine practice may be supported by ASRM or other clinical society guidance even if the FDA label does not enumerate that specific use. Your physician should identify the exact basis of the not-FDA-approved finding and respond to it with the applicable regulatory status and clinical society recognition.

## Your Federal Appeal Rights

• Internal appeal — file within 180 days of the denial. Humana must respond within 30 days (pre-service).
• External review (ACA §2719) — if the internal appeal is denied, request independent external review within four months. The IRO's decision is binding on Humana.
• Expedited review — if your physician certifies urgent clinical need, a 72-hour external review is available.
• ERISA §503 — employer self-funded plan members retain full-and-fair review rights and may seek federal court review after exhausting internal and external remedies.

## What to Gather

• Humana's denial letter — identify precisely which element of your IVF treatment Humana has characterized as not FDA-approved.
• Regulatory status documentation — obtain from your physician or the device/medication manufacturer the relevant FDA clearance, approval, or labeling information for the item in question.
• Clinical practice basis — a statement from your reproductive endocrinologist explaining the clinical role of the item, whether it is consistent with ASRM or other applicable guideline-organization practice standards, and why it is a necessary component of your treatment plan.
• Humana's coverage policy — obtain the current published policy and identify how it defines FDA approval or clearance requirements, to ensure your response addresses its specific language.
• Coding review — if the denial may be based on a billing code issue, have your physician's billing team confirm that the procedure was coded correctly.

## Criteria-Mapping Structure

For each element of Humana's not-FDA-approved determination, prepare a two-column table: the policy's stated requirement in the left column and the specific regulatory fact, guideline-organization reference, or physician attestation that responds to it in the right column. If multiple components of your treatment are implicated, address each one separately.